GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Summary
GSK, a British drug company, is buying the US cancer treatment firm Nuvalent for $10.6 billion. This deal adds new lung cancer drugs to GSK’s products, with key treatments expected to launch soon if approved by regulators.Key Facts
- GSK is buying Nuvalent, a cancer drug company based in Boston, for $10.6 billion.
- Nuvalent has two late-stage lung cancer treatments under review by the US Food and Drug Administration (FDA), with decisions due in September and November.
- The drugs zidesamtinib and neladalkib target non-small cell lung cancer, especially in middle-aged adults who mostly do not smoke.
- These drugs aim to provide longer, better-tolerated treatment by targeting specific cancer mutations.
- GSK’s new chief executive, Luke Miels, took over earlier this year and made this its biggest acquisition ever.
- The deal supports GSK's goal to grow sales and profit from 2027 and expand in lung cancer treatments.
- GSK also acquired another biotech company, RAPT, in January for developing allergy treatments.
- GSK aims to reach more than £40 billion in annual sales by 2031 with help from new products like those from Nuvalent.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.